2025 Half-Year Results: Aton Confirms its Recovery

Aton, a player in the medical sciences sector, reports encouraging half-year results. For the period from January 1 to June 30, 2025, revenue reached €287,000, representing positive momentum thanks to the performance of Inoviem Scientific. The net loss of €0.5 million marks a significant improvement compared to a loss of €1.1 million in 2024. This improvement was supported by reduced expenses and a debt-to-equity conversion in 2024. Cash position as of June 30 remained stable at €0.1 million.

The restructuring strategy continues to bear fruit. Inoviem Scientific is progressing while PIMS Technology is preparing to launch its molecular analyzer. B Cell Design is expanding internationally through a strategic partnership, strengthening Aton's position in the global diagnostics market. The coming months should see this momentum reinforced by the ramp-up of subsidiaries to consolidate the group's positions.